Research
Analysis: Cure SMA’s Risk/Benefit Survey
One of Cure SMA’s top priorities is to relay the SMA community’s treatment experiences and preferences to the United States Food and Drug Administration (FDA). […]
Read More ›Identifying Biomarkers of Spinal Muscular Atrophy for Further Development
An important part of Cure SMA’s core mission is to carry out and support research that will improve the quality of life for all people […]
Read More ›Biohaven Completes Enrollment in Pivotal Phase 3 Study
Recently, Biohaven released a statement on the completed enrollment of their pivotal Phase 3 Study of Taldefgrobep Alfa in people with SMA. Check out Biohaven’s […]
Read More ›Clinical Research and Drug Development Session Highlights from 2023 SMA Research & Clinical Care Meeting
At the end of June, SMA researchers and clinicians from around the world met in Orlando, Florida, for the 2023 Annual SMA Research & Clinical […]
Read More ›Cure SMA Announces Expanded Phase 3 of Real World Evidence Collaboration
Cure SMA is pleased to announce the launch of an expanded Phase 3 of the Real World Evidence Collaboration. The collaboration was established to leverage […]
Read More ›SMA Scientists and Clinicians from Around the World Gather at the 27th Annual SMA Research & Clinical Care Meeting
At the end of June, SMA researchers and clinicians from around the world met in Orlando, Florida, for the 2023 Annual SMA Research & Clinical […]
Read More ›Cure SMA’s 2022 State of SMA Report
Cure SMA is pleased to announce the launch of the second annual State of SMA report. The purpose of this report is to share highlights […]
Read More ›Cure SMA Awards $100,000 Grant to Saravanan Arumugam, PhD, Universidad de Seville
Saravanan Arumugam, PhD, was awarded $100,000 for his research project, “Role of Cytosolic and Mitochondrial Ca2+ in the Pathogenesis of Spinal Muscular Atrophy.” Dr. Arumugam’s […]
Read More ›Cure SMA Awards $75,000 Grant to Lyndsay Murray, PhD, University of Edinburgh
Lyndsay Murray, PhD, was awarded $75,000 for her research project, “Evaluating the impact of sequential versus simultaneous administration of SMN-inducing compounds on motor unit recovery […]
Read More ›Biohaven’s Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
This week, Biohaven announced that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, […]
Read More ›